Thomas Shrader from BTIG set a price target of $48 for NASDAQ:ARCT, indicating a significant potential upside from its current trading price.
Arcturus reported a quarterly loss of $1.11 per share, missing the Zacks Consensus Estimate significantly.
The company’s revenue for the quarter ending December 2024 was $22.77 million, falling short of expectations and showing a decline from the previous year.
Arcturus Therapeutics (NASDAQ:ARCT) is a biotechnology company focused on developing RNA medicines for rare diseases and vaccines. The company operates within the competitive Zacks Medical – Biomedical and Genetics industry. On March 10, 2025, Thomas Shrader from BTIG set a price target of $48 for ARCT, while the stock was trading at $14.55, indicating a significant potential upside.
Despite the optimistic price target, Arcturus reported a quarterly loss of $1.11 per share, missing the Zacks Consensus Estimate of a $0.34 loss. This represents a negative surprise of 226.47%. The loss increased from $0.32 per share a year ago, highlighting financial challenges. However, in the previous quarter, ARCT reported a loss of $0.26 per share, beating expectations of a $0.70 loss, resulting in a positive surprise of 62.86%.
Arcturus’s revenue for the quarter ending December 2024 was $22.77 million, falling short of the Zacks Consensus Estimate by 60.60%. This is a decline from $33.99 million in the same quarter the previous year. Despite this miss, the company has exceeded consensus revenue estimates twice in the last four quarters, showing some resilience in its financial performance.
Currently, ARCT is trading at $14.05, a decrease of approximately 3.43% or $0.50. The stock has fluctuated between $14 and $14.54 today. Over the past year, ARCT has seen a high of $45 and a low of $14, reflecting significant volatility. The company’s market capitalization is approximately $381 million, with a trading volume of 43,420 shares on the NASDAQ exchange.
